Finerenone initiation in US adults with CKD and T2D reduced median UACR by 33% at 4 months and 38% at 12 months, with a 1.2% incidence of hyperkalemia by 12 months.
Cohort (n=15,948)
Yes
Does finerenone reduce urine albumin-to-creatinine ratio in adults with chronic kidney disease and type 2 diabetes?
In real-world US practice, finerenone initiation in patients with CKD and T2D was associated with significant and sustained reductions in UACR and a low incidence of hyperkalemia.
INTRODUCTION: In 2021, finerenone - a novel, selective nonsteroidal mineralocorticoid receptor antagonist - was approved in the USA to treat adults with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study aimed to describe characteristics and short-term outcomes of patients prescribed finerenone since regulatory approval. METHODS: This was a retrospective cohort study using claims and electronic health records data from the OM1 Real-World Data Cloud™. A total of 15,948 US adults with a previous diagnosis of CKD and T2D who initiated 10 mg or 20 mg finerenone between July 2021 and August 2023 were included. Dosing was evaluated at baseline and over up to 12-month follow-up. Change from baseline in urine albumin-to-creatinine ratio (UACR) was evaluated at 4 and 12 months (among 913 and 443 patients, respectively, with available repeat UACR values). Hyperkalemia occurrence was determined at 12 months and over total follow-up. RESULTS: Median follow-up was 7.2 months. Mean age was 70.3 years, and 44.1% were female. At baseline (-365; 0 days), 70% had CKD stage 3; for patients with UACR measurements, 80.8% had moderate/severe albuminuria (≥30 mg/g). Median UACR was 203 mg/g. Co-medication use was ACE inhibitors/ARBs (51%), SGLT2is (38%), and GLP-1 RAs (26%). 86% of patients initiated 10 mg finerenone, and among 2,212 patients still under observation at 12 months, 70% were on 10 mg. For finerenone initiators with available UACR data, UACR was reduced by 33% at 4 months and 38% at 12 months. Hyperkalemia occurred in 1.2% of the cohort by 12 months (incidence 2.0 per 100 person-years). CONCLUSION: Patients who initiated finerenone had a notable reduction in median UACR at 4 months, sustained at 12 months; hyperkalemia occurrence appeared to be low. These initial findings from US clinical practice should be complemented by results from other real-world cohorts of patients started on finerenone.
Kövesdy et al. (Thu,) conducted a cohort in Chronic kidney disease and type 2 diabetes (n=15,948). Finerenone was evaluated on Change from baseline in urine albumin-to-creatinine ratio (UACR) and hyperkalemia occurrence. Finerenone initiation in US adults with CKD and T2D reduced median UACR by 33% at 4 months and 38% at 12 months, with a 1.2% incidence of hyperkalemia by 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: